Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 2Withdrawn 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Lymphoid 1

Conditions

Lymphoma, Large B-Cell, Diffuse 1Lymphoma 1Leukemia, Myeloid, Acute 1Dendritic Cell Sarcoma, Interdigitating 1Acromesomelic dysplasia, Maroteaux type 1

Interventions

Rituximab 20Cyclophosphamide 18Etoposide 11Vincristine 10Doxorubicin 10fludarabine phosphate 9Prednisone 9Filgrastim 9Radiotherapy 8Peripheral Blood Stem Cell Transplantation 8Cytarabine 8Methotrexate 7Melphalan 7Dexamethasone 6fludarabine 4Cyclosporine 4Antilymphocyte Serum 4duvelisib 3belinostat 3Thiotepa 3Tacrolimus 3Nivolumab 3Mycophenolic Acid 3Lenalidomide 3Ifosfamide 3Gemcitabine 3Carmustine 3Busulfan 3Alemtuzumab 3sargramostim 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Lymphoma × pevonedistat × Clear all
NCT01415765 2019-12-17

MLN4924 Compared With MLN4924 Plus Chemotherapy for Large B-cell Lymphoma

National Institutes of Health Clinical Center (CC)

Phase 1/2 Withdrawn
LymphoidSarcoma

Acromesomelic dysplasia, Maroteaux type, Lymphoma, Lymphoma, Large B-Cell, Diffuse, Dendritic Cell Sarcoma, Interdigitating

Data powered by HemOnc (CC BY 4.0) Colophon âš¡